KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Income from Non-Controlling Interests (2019 - 2025)

Royalty Pharma's Income from Non-Controlling Interests history spans 7 years, with the latest figure at $141.7 million for Q4 2025.

  • For Q4 2025, Income from Non-Controlling Interests rose 12.34% year-over-year to $141.7 million; the TTM value through Dec 2025 reached $553.2 million, up 17.26%, while the annual FY2025 figure was $553.2 million, 17.26% up from the prior year.
  • Income from Non-Controlling Interests for Q4 2025 was $141.7 million at Royalty Pharma, down from $156.0 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $366.0 million in Q2 2021 and bottomed at -$153.9 million in Q4 2022.
  • The 5-year median for Income from Non-Controlling Interests is $121.8 million (2021), against an average of $120.0 million.
  • The largest annual shift saw Income from Non-Controlling Interests plummeted 436.37% in 2022 before it skyrocketed 2255.39% in 2025.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at $45.8 million in 2021, then tumbled by 436.37% to -$153.9 million in 2022, then surged by 245.02% to $223.2 million in 2023, then tumbled by 43.5% to $126.1 million in 2024, then increased by 12.34% to $141.7 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Income from Non-Controlling Interests are $141.7 million (Q4 2025), $156.0 million (Q3 2025), and $60.5 million (Q2 2025).